Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

BACKGROUND: Pralatrexate is a dihydrofolate reductase (DHFR) inhibitor with high affinity for reduced folate carrier 1 (RFC-1) and folylpolyglutamate synthetase (FPGS), resulting in extensive internalization and accumulation in tumour cells. Pralatrexate is approved in the US for the treatment of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Serova, M, Bieche, I, Sablin, M-P, Pronk, G J, Vidaud, M, Cvitkovic, E, Faivre, S, Raymond, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031902/
https://www.ncbi.nlm.nih.gov/pubmed/21179031
http://dx.doi.org/10.1038/sj.bjc.6606063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031902/
https://www.ncbi.nlm.nih.gov/pubmed/21179031
http://dx.doi.org/10.1038/sj.bjc.6606063

Ejemplares similares